Closantel; a Veterinary Drug With Potential Severe Morbidity in Humans

Closantel; a Veterinary Drug With Potential Severe Morbidity in Humans Publisher Pubmed

Tabatabaei SA¹ ; Soleimani M¹ ; Mansouri MR¹ ; Mirshahi A¹ ; Inanlou B¹ ; Abrishami M¹ ; Pakrah AR¹ ; Masarat H¹

Show Affiliations

1. Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: BMC Ophthalmology Published:2016

Abstract

Background: Closantel is a halogenated salicylanilide with a potent anti parasitic activity. It is widely used in management of parasitic infestation in animals, but is contraindicated in humans. Case presentation: A 34-year-old man with depression was referred to our center with progressive loss of vision in both eyes 10 days after unintentional ingestion of three 500 mg tablets of Closantel. On fundus examination, left optic disc margin was blurred. His bilateral visual acuity was no light perception (NLP) despite prescribed IV erythropoietin injections 20,000 units daily for 3 days and 1gr intravenous methylprednisolone acetate for 3 days followed by 1 mg/kg oral prednisolone. On macular optical coherence tomography (OCT), a disruption in outer retina was observed. Electroretinogram and visual evoked potential tests showed visual pathway involvement. Conclusions: Destruction of neurosensory retina and visual pathways after accidental Closantel use is related to severe visual loss. This case alerts us about the destructive effect of this drug on humans even in low dosage which necessitates preventive efforts to reduce the chance of this morbid side effect. © 2016 The Author(s).

Style	Citing Format
MLA	Tabatabaei SA, et al.. "Closantel; a Veterinary Drug With Potential Severe Morbidity in Humans." BMC Ophthalmology, vol. 16, no. 1, 2016, pp. -.
APA	Tabatabaei SA, Soleimani M, Mansouri MR, Mirshahi A, Inanlou B, Abrishami M, Pakrah AR, Masarat H (2016). Closantel; a Veterinary Drug With Potential Severe Morbidity in Humans. BMC Ophthalmology, 16(1), -.
Chicago	Tabatabaei SA, Soleimani M, Mansouri MR, Mirshahi A, Inanlou B, Abrishami M, Pakrah AR, Masarat H. "Closantel; a Veterinary Drug With Potential Severe Morbidity in Humans." BMC Ophthalmology 16, no. 1 (2016): -.
Harvard	Tabatabaei SA et al. (2016) 'Closantel; a Veterinary Drug With Potential Severe Morbidity in Humans', BMC Ophthalmology, 16(1), pp. -.
Vancouver	Tabatabaei SA, Soleimani M, Mansouri MR, Mirshahi A, Inanlou B, Abrishami M, et al.. Closantel; a Veterinary Drug With Potential Severe Morbidity in Humans. BMC Ophthalmology. 2016;16(1):-.
BibTex	@article{ author = {Tabatabaei SA and Soleimani M and Mansouri MR and Mirshahi A and Inanlou B and Abrishami M and Pakrah AR and Masarat H}, title = {Closantel; a Veterinary Drug With Potential Severe Morbidity in Humans}, journal = {BMC Ophthalmology}, volume = {16}, number = {1}, pages = {-}, year = {2016} }
RIS	TY - JOUR AU - Tabatabaei SA AU - Soleimani M AU - Mansouri MR AU - Mirshahi A AU - Inanlou B AU - Abrishami M AU - Pakrah AR AU - Masarat H TI - Closantel; a Veterinary Drug With Potential Severe Morbidity in Humans JO - BMC Ophthalmology VL - 16 IS - 1 SP - EP - PY - 2016 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract